The partnership aims to harness the power of automation to make production processes more efficient
Nephron Pharmaceuticals is partnering with Clemson University to create a robotic solution for syringe-filling automation to enhance sterile manufacturing in the pharmaceutical production process. This improvement will aid in keeping up with growing hospital demands for these products.
The partnership aims to harness the power of technology and automation to make production processes more efficient. To do so, Nephron is enlisting the expertise of the College of Engineering, Computing and Applied Science professor and researcher Yue "Sophie" Wang and mechanical engineering doctoral student Brandon Delspina and mechanical engineering master's student Yu "Gloria" Zhang.
Their robotics research for syringe automation will support the Nephron 503B Outsourcing Facility, a cGMP manufacturer providing sterile, pre-filled medications to address persistent drug shortages in hospitals and medical facilities across America.
"When the External Affairs' Office of Corporate Partnerships and Strategic Initiatives approached us about this project we were excited to get involved," said Wang, associate professor of mechanical engineering. "Our work in robotics can have a tremendous impact on individuals across the country and we are looking forward to working on this because of its benefits for the many patients Nephron serves."
Based in West Columbia, Nephron is a certified woman-owned business and one of the fastest-growing companies in South Carolina. This is Nephron's first partnership with the University and was developed through External Affairs' Office of Corporate Partnerships and Strategic Initiatives at Clemson University.
"Industry needs are changing at a rapid rate and Clemson is equipped to support companies like Nephron. Together, we have created a mutually beneficial project to enhance their capabilities while providing the University's students with unique, hands-on research experience," said Angie Leidinger, Vice President for External Affairs. "This partnership is a testament to the work happening at Clemson and we're looking forward to this collaboration, which will advance their business and benefit South Carolinians."
Nephron CEO, Lou Kennedy, said: "Working together with Clemson's world-class researchers and engineers, we can ensure that the pharmaceutical manufacturing process remains safe, and we can deliver life-saving drugs to patients and hospitals across the country."